Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-22-059261
Filing Date
2022-12-01
Accepted
2022-12-01 20:46:19
Documents
2
Period of Report
2022-11-29

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1662
2 POA DOCUMENT poa.txt EX-24 2997
  Complete submission text file 0001209191-22-059261.txt   6063
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Issuer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O AKCEA THERAPEUTICS 55 CAMBRIDGE PARKWAY, STE 100 CAMBRIDGE MA 02142
Business Address
Goldberg Jeff Marc (Reporting) CIK: 0001703061 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37722 | Film No.: 221440109